Table 3.
Results from invariance testing of indirect effects across treatment sites (site 1 versus site 2) and delivery modes (face–face versus telehealth)
| Model | Indirect effect path | Site 1 versus site 2 | Face–face versus telehealth | ||||||
|---|---|---|---|---|---|---|---|---|---|
| b1–b2 (SE) | Lower 2.5% | Upper 2.5% | p-value | b1–b2 (SE) | Lower 2.5% | Upper 2.5% | p-value | ||
| 1 | Path a × b | .00 (.02) | − .04 | .02 | .80 | .01 (.02) | − .03 | .04 | .78 |
| Path a × d | − .02 (.03) | − .09 | .02 | .48 | .01 (.03) | − .04 | .06 | .85 | |
| Path a × b × c | .00 (.01) | − .02 | .01 | .98 | .01 (.01) | − .01 | .02 | .50 | |
| 2 | Path a × b | − .01 (.02) | − .07 | .03 | .68 | − .01 (.02) | − .06 | .03 | .69 |
| Path a × d | − .03 (.03) | − .11 | .02 | .31 | − .01 (.03) | − .07 | .05 | .77 | |
| Path a × b × c | .00 (.01) | − .03 | .01 | .85 | − .01 (.01) | − .03 | .00 | .35 | |
| 3 | Path a × b | .02 (.04) | − .05 | .09 | .53 | .00 (.04) | − .08 | .07 | .97 |
| Path a × d | − .10 (.06) | − .24 | .00 | .09 | − .04 (.05) | − .15 | .05 | .43 | |
| Path a × b × c | .01 (.01) | − .03 | .03 | .63 | − .01 (.02) | − .05 | .01 | .52 | |
*p-value < .05